Clinical Trial Update: Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research [EARLY_Phase 1]

View source ↗

Summary

This document reports an EARLY Phase 1 clinical trial evaluating Meta10-BCMA for relapsed/refractory plasma cell neoplasms. The therapy uses metabolically armed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Al Amyloidosis
• Multiple Myeloma
• Plasma Cell Leukemia

Drugs mentioned

• Meta10-BCMA (metabolically armed BCMA CAR-T cell therapy)

Snippet

Sponsor: Anhui Provincial Hospital | Conditions: Multiple Myeloma (MM), Plasma Cell Leukemia (PCL) | EARLY_Phase 1 | Status: RECRUITING